Application
- For high-throughput screening of FTase inhibitors and evaluation of drug modulators.
Key Features
- Safe. Non-radioactive assay.
- Homogeneous and convenient. “Mix-incubate-measure” type assay. No wash and reagent transfer steps are involved.
- High-throughput. A Z’-factor of 0.8 and higher is routinely observed in a 384-well format. Can be readily automated to assay thousands of samples per day.
Method
- FL340/550 nm
Samples
- Compounds that affect farnesyltransferase activity
Species
- All
Procedures
- 60 min
Size
- 400 tests in 384well plate
Detection Limit
- NA
Shelf Life
- 6 months
More Details
FARNESYLTRANSFERASE (FTase, EC 2.5.1.58) catalyzes the transfer of a farnesyl group from farnesyl pyrophosphate to the cysteine residue of the C-terminus of target proteins. When not properly regulated, farnesylated proteins, including the Ras superfamily of small GTPases, can lead to developmental disorders and cancer. Simple, direct and high-throughput inhibitor screening assays find wide applications for oncology research. BioAssay Systems’ EIFT-400 assay kit provides a convenient fluorimetric method to screen for potential FTase inhibitors. In this assay, FTase reacts with farnesyl pyrophosphate and a dansyl-peptide substrate with measurable fluorescence at λem/ex = 340/550 nm. Inhibition is determined by the decrease in fluorescence.
Reviews
There are no reviews yet.